New advances in the treatment of inflammatory bowel disease;Novedades sobre los tratamientos para la enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 36, Issue SUPPL.2, 2013, Pages 21-29

  Chaparro, María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Adalimumab; Crohn disease; Golimumab; Inflammatory bowel disease; Infliximab; Natalizumab; Thiopurines; Ulcerative colitis; Vedolizumab

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; VEDOLIZUMAB;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL PRACTICE; CROHN DISEASE; DRUG EFFICACY; DRUG POTENTIATION; ENTERITIS; MEDICAL INFORMATION; POSTOPERATIVE PERIOD; RECURRENT DISEASE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADALIMUMAB; COLITIS ULCEROSA; CROHN DISEASE; ENFERMEDAD DE CROHN; ENFERMEDAD INFLAMATORIA INTESTINAL; GOLIMUMAB; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB; NATALIZUMAB; THIOPURINES; TIOPURINAS; ULCERATIVE COLITIS; VEDOLIZUMAB;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886291834     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/S0210-5705(13)70050-5     Document Type: Article

References (41)

1. Sandborn B.J., Hardiman Y., Huang M., Harris-Collazo R., Ballard E., Travis S. Efficacy of budesonide MMX in reduction of symptoms in patients with mild-to-moderately active ulcerative colitis: a pooled analysis of the CORE I and CORE II studies. Gastroenterology 2013, 144(Suppl 1):S233-S234.
2. Lichtenstein G.R., Sandborn W.J., Huang B., Hardiman Y., Bagin R., Yeung P., et al. Budesonide MMX9mg induces remission in mild-to-moderately active ulcerative colitis patients regardless of prior history of 5-ASA therapy. Gastroenterology 2013, 144(Suppl 1):S234.
3. Dignass A., Stoynov S., Dorofeyev A., Grigorieva G., Tomsova E., Altorjay I., et al. Once daily dosing of 9mg budesonide (Budenofalk) is therapeutic equivalent to a three-times daily dosing of 3mg budesonide for the treatment of active Crohn's disease: a randomized, double-blind, double-dummy, multicenter phase III study. Gastroenterology 2013, 144(Suppl 1):S233.
4. Laharie D., Bourreille A., Branche J., Allez M., Bouhnik Y., Filippi J., et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012, 380:1909-1915.
5. Lowenberg M., Duijvis N., Ponsioen C., Van den Brink G.R., Bernelman W., Fockens P., et al. Reduced of length hospitalization and treatment costs with infliximab versus ciclosporin in patients with severe ulcerative colitis. Gastroenterology 2013, 144(Suppl 1):S428.
6. Protic M., Frei P., Radojicic Z., Schoepfer A., Juillerat P., Mottet C., et al. Comparative long-term outcomes of tacrolimus, cyclosporine and infliximab for steroid-refractory ulcerative colitis-week 52 results Swiss IBD Cohort Study. Gastroenterology 2013, 144(Suppl 1):S428-S429.
7. Armuzzi A., Pugliese D., Danese S., Rizzo G., Marzo M., Felice C., et al. Long-term outcome of treatment with infliximab in patients with steroid-dependent ulcerative colitis. Gastroenterology 2013, 144(Suppl 1):S427.
8. Reinisch W., Sandborn W.J., Hommes D.W., D'Haens G., Hanauer S., Schreiber S., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
9. Sandborn W.J., Van Assche G., Reinisch W., Colombel J.F., D'Haens G., Wolf D.C., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265. e1-3.
10. Ghosh S., Wolf D., Sandborn B.J., Colombel J.F., Zhou Q., Lazar A., et al. Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA. Gastroenterology 2013, 144Suppl1:S230.
11. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
12. Oussalah A., Chevaux J.B., Fay R., Sandborn W.J., Bigard M.A., Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010, 105:1142-1149.
13. Chaparro M., Panes J., García V., Manosa M., Esteve M., Merino O., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011, 45:113-118.
14. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
15. Jeuring S., Van den Heuvel T., Romberg-Camps M., Oostenbrug L., Hameeteman W., Masclee A., et al. Concomitant use of immunomodulators increases long term response to infliximab in ulcerative colitis -a population-based IBD-SI cohort study. Gastroenterology 2013, 144(Suppl 1):S431.
16. Hayes M., Sakuraba A., Stein A.C., Hanauer S. A comparison of efficacy, pharmacokinetics and immunogenicity in patients with ulcerative colitis receiving infliximab monotherapy versus combination therapy. Gastroenterology 2013, 144(Suppl 1):S430.
17. Kennedy N., Reynolds S., Dattani R., Nayee H., Felwick R., Harris R., et al. Thiopurine withdrawal for sustained remission in IBD: a UK multicentre study. Gastroenterology 2013, 144(Suppl 1):S433-S434.
18. Sofi A., Ali A., Khuder S., Nawras A. Meta-analysis: maintenance of remission following discontinuation of infliximab in patients with Crohn's disease. Gastroenterology 2013, 144(Suppl 1):S637.
19. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450. e1; quiz 716.
20. Savarino E., Bodini G., Dulbecco P., Marabotto E., Assandri L., Bruzzone L., et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease -a randomized trial. Gastroenterology 2013, 144Suppl1:S21.
21. Sandborn W.J., Yednock T.A. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003, 98:2372-2382.
22. Podolsky D.K. Selective adhesion-molecule therapy and inflammatory bowel disease-a tale of Janus?. N Engl J Med 2005, 353:1965-1968.
23. Neumann F., Zohren F., Haas R. The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 2009, 9:1099-1106.
24. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D.H., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007, 132:1672-1683.
25. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375-381.
26. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
27. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
28. Deepak P., Stobaugh D., Ehrenpreis E.D. Risk of infections with natalizumab therapy among patients with Crohn's disease: an analysis of the Food and Drug Administration adverse event reporting system. Gastroenterology 2013, 144(Suppl 1):S415.
29. Rutgeerts P., Sandborn B.J., Reinisch W., Xu J., Milch C., Fox I., et al. Sustained therapeutic benefit of vedolizumab throughout 1 year in Crohn's disease in Gemini II, a randomized placebo-controlled, double-blind, multicenter study. Gastroenterology 2013, 144(Suppl 1):S21.
30. Colombel J.F., Sands B.E., Feagan B., Loftus E.V., Sankoh S., Fox I., et al. Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. Gastroenterology 2013, 144(Suppl 1):S113.
31. Ueda N., Tsukamoto H., Mitoma H., Ayano M., Tanaka A., Ohta S., et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm Bowel Dis 2013, 19:1224-1231.
32. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
33. Sandborn W.J., Feagan B.G., Marano C., Zhang H., Strauss R., Johanns J., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Gastroenterology 2013, doi:10. 1053/j. gastro.2013.05. 048. [Epub ahead of print].
34. Adedokun O., Xu Z., Marano C., Strauss R., Zhang H., Johanns J., et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderatelytoseverely active ulcerative colitis: results from phase 2/3 induction and maintenance studies. Gastroenterology 2013, 144(Suppl 1):S228-S229.
35. D'Haens G., Colombel J.F., Sandborn B.J., Rutgeerts P., Feagan B. Safety and efficacy of laquinimod in inducing clinical and biochemical improvement in active Crohn's disease: results of an exploratory trial. Gastroenterology 2013, 144(Suppl 1):S21.
36. Annaloro C., Onida F., Lambertenghi Deliliers G. Autologous hematopoietic stem cell transplantation in autoimmune diseases. Expert Rev Hematol 2009, 2:699-715.
37. Oyama Y., Craig R.M., Traynor A.E., Quigley K., Statkute L., Halverson A., et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005, 128:552-563.
38. Cassinotti A., Annaloro C., Ardizzone S., Onida F., Della Volpe A., Clerici M., et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008, 57:211-217.
39. Scime R., Cavallaro A.M., Tringali S., Santoro A., Rizzo A., Montalbano L., et al. Complete clinical remission after high-dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn's disease refractory to immunosuppressive and immunomodulator therapy. Inflamm Bowel Dis 2004, 10:892-894.
40. Kreisel W., Potthoff K., Bertz H., Schmitt-Graeff A., Ruf G., Rasenack J., et al. Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant 2003, 32:337-340.
41. Hawkey C., Allez M., Ardizzone S., Clark L., Colombel J.F., Danese S., et al. Clinical and endoscopic improvement following hemopoietic stem cell transplantation vs mobilisation alone in Crohn's disease. Gastroenterology 2013, 144(Suppl 1):S21-S22.